Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031044 · ClinicalTrials.gov registry record · Phase 1
Adding New Drugs for HIV Infected Patients Failing Current Therapy
A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 9
- Study locations
NCT00031044 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 50 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (89% lower). The trial reports 9 study locations across 6 states.
The verdict
NCT00031044, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 9
- Study locations
Study Summary
Even though powerful anti-HIV drug combinations have been successful in patients with little or no prior anti-HIV therapy, studies have shown that these treatments are less effective in patients who have been treated with nucleoside analogues. This study will test the safety and effectiveness of adding one or two new drugs to a personalized anti-HIV regimen for patients whose previous HIV treatments have failed.
Conditions Studied
Interventions
- DRUG Enfuvirtide
- DRUG Amdoxovir
Study Locations (9)
Massachusetts
- Harvard (Massachusetts General Hosp) - Boston
- Brigham and Womens Hosp - Boston
New York
- Cornell Univ Med Ctr - New York
- Columbia Presbyterian Med Ctr - New York
Ohio
- Case Western Reserve Univ - Cleveland
- MetroHealth Med Ctr - Cleveland
Colorado
- Univ of Colorado Health Sciences Ctr - Denver
Florida
- Miami University - Miami
Other
- Univ of Puerto Rico - San Juan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Est. Completion | 2004-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00031044
The ClinicalTrials.gov registry entry for NCT00031044 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (89% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Enfuvirtide is the first listed.
NCT00031044 reports 9 study locations spanning 6 distinct geographic areas - top geographies include Massachusetts, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT00031044 about?
NCT00031044 is a clinical study titled "Adding New Drugs for HIV Infected Patients Failing Current Therapy". Even though powerful anti-HIV drug combinations have been successful in patients with little or no prior anti-HIV therapy, studies have shown that these treatments are less effective in patients who have been treated with nucleoside analogues. This study will test the safety and effectiveness of add...
What is the current status of trial NCT00031044?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. Estimated completion is 2004-11.
What conditions does trial NCT00031044 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00031044?
The interventions under investigation include: Enfuvirtide (DRUG), Amdoxovir (DRUG).
Who is sponsoring clinical trial NCT00031044?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00031044 being conducted?
This trial has 9 study locations across Colorado, Florida, Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.